Medical Treatments: Cost Effectiveness
The question
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 27 October 2025 to Question 77609 on Medical Treatments: Cost Effectiveness, if he will instruct NICE to review the adequacy of the Quality-Adjusted Life Year threshold for innovative medicines.
Answered by Dr Zubir Ahmed
The pharmaceutical sector and the innovative medicines it produces are critical to our national interest, helping people access life changing treatments, reducing pressure on the health service over the longer-term, and ensuring we have a National Health Service that is fit for the future.
That is why through our Life Sciences Sector Plan, we have committed to working with industry to accelerate growth in spending on innovative medicines, compared to the previous decade. Our 10-Year Health Plan set out how we’d reform National Institute for Health and Care Excellence.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →